Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for post...
2024-04-23 05:21:00 ET We recently learned that spatial technology company Matterport (NASDAQ: MTTR) , which provides the space-mapping technology used for 3D home tours and many other applications, has agreed to be acquired by real estate giant CoStar (NASDAQ: CSGP) . T...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 7.2% to $0.04 on volume of 426,309,096 shares PROSHARES TRUST (SQQQ) rose 1.8% to $12.07 on volume of 171,048,374 shares AGBA Group Holding Limited (AGBA) rose 157.5% to $1.03 on volume of 121,894,6...
SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering mak...
2024-04-18 06:52:32 ET Summary Proposed bill may fast track TikTok's divestment from ByteDance or face a U.S. ban. Micron Technology to receive funding from the U.S. for chipmaking projects. 23andMe CEO eyes taking DNA-testing company private. Listen below or on the ...
2024-04-18 04:44:39 ET More on 23andMe 23andMe (ME) Q3 2024 Earnings Call Transcript 23andMe falls 20% after earnings, breakup speculation Seeking Alpha's Quant Rating on 23andMe Historical earnings data for 23andMe Read the full article on Seeking ...
2024-04-15 22:15:03 ET Citigroup analyst issues NEUTRAL recommendation for ME on April 15, 2024 08:50PM ET. The previous analyst recommendation was Neutral. ME was trading at $0.4016 at issue of the analyst recommendation. Historical Analyst Recommendations Latest ...
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting ULBP6 23ME-00610, antibody targeting CD200R1: Preclinical data will be presented on targetin...
2024-03-24 03:23:00 ET If you're an individual investor who wants to invest like a billionaire fund manager, I've got good news. Following billionaires is relatively easy because the U.S. Securities and Exchange Commission makes anyone who manages over $100 million in assets report their tr...
23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector function SOUTH S...
News, Short Squeeze, Breakout and More Instantly...
23andMe Holding Co. Company Name:
ME Stock Symbol:
NASDAQ Market:
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.’s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRA ...
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmac...
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resul...